
AJUNTAMENT D'ALCOI
Website

Generalitat Valenciana
Website

Ayuntamiento de Valencia
Website

Cicloplast
Website

Ayuntamiento de Onil
Website

Anarpla
Website

Ayuntamiento de Mislata
Website

nlWA, North London Waste Authority
Website

Ayuntamiento de Salinas
Website

Zicla
Website

Fondazione Ecosistemi
Website

PEFC
Website

ALQUIENVAS
Website

DIPUTACI� DE VAL�NCIA
Website

AYUNTAMIENTO DE REQUENA
Website

UNIVERSIDAD DE ZARAGOZA
Website

OBSERVATORIO CONTRATACIÓN PÚBLICA
Website

AYUNTAMIENTO DE PAIPORTA
Website

AYUNTAMIENTO DE CUENCA
Website

BERL� S.A.
Website

CM PLASTIK
Website

TRANSFORMADORES INDUSTRIALES ECOL�GICOS

INDUSTRIAS AGAPITO
Website

RUBI KANGURO
Website
If you want to support our LIFE project as a STAKEHOLDER, please contact with us: life-future-project@aimplas.es
In this section, you can access to the latest technical information related to the FUTURE project topic.
Discovery of new and highly effective quadruple FFA1 and PPAR?/?/? agonists as potential anti-fatty liver agents
Non-alcoholic fatty liver disease (NAFLD) has become the most common hepatic disease, while no drug was approved until now. The previous study reported that the quadruple FFA1/PPAR-?/?/? agonist RLA8 provided better efficacy than obeticholic acid on NASH. In the present study, two design strategies were introduced to explore better quadruple FFA1/PPAR-?/?/? agonists with improved metabolic stability. These efforts ultimately resulted in the identification of ZLY18, a quadruple FFA1/PPAR-?/?/? agonist with twice higher metabolic half-life than RLA8 in the liver microsome. In the triton-1339W-induced hyperlipidemic model, ZLY18 reversed hyperlipidemia to an almost normal level, which exhibited far stronger lipid-lowering effects than that of RLA8. Moreover, ZLY18 significantly decreased steatosis, hepatocellular ballooning, inflammation and liver fibrosis in NASH model even better than RLA8. Further mechanism studies suggested that ZLY18 exerts stronger effects than RLA8 on the regulation of the gene related to lipid synthesis, oxidative stress, inflammation and fibrosis. In addition, ZLY18 is more effective than pirfenidone in the prevention of CCl4-induced liver fibrosis. Besides, ZLY18 has an acceptable safety profile in the acute toxicity study at a high dose of 500?mg/kg. Therefore, ZLY18 represents a novel and highly promising quadruple FFA1/PPAR-?/?/? agonist worth of further investigation and development.

» Author: Zongtao Zhou, Qiang Ren, Shixuan Jiao, Zongyu Cai, Xinqian Geng, Liming Deng, Bin Wang, Lijun Hu, Luyong Zhang, Ying Yang, Zheng Li
» Publication Date: 05/02/2022
C/ Gustave Eiffel, 4
(València Parc Tecnològic) - 46980
PATERNA (Valencia) - SPAIN
(+34) 96 136 60 40
Project Management department - Sustainability and Industrial Recovery
life-future-project@aimplas.es
